Sensus Healthcare, Inc.
SRTSNasdaq
$3.02
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↓ -30.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$49.7M
Enterprise Value
$31.4M
P/E
—
P/S
2.2
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-1.5%
Dividend Yield
—
Revenue (TTM)
$22.5M
Net Income (TTM)
-$7.8M
Free Cash Flow (TTM)
-$740,000.00
Gross Margin
37.7%
Operating Margin
-53.3%
Net Margin
-34.5%
ROE
-17.1%
ROIC
-34.9%
Debt / Equity
—
Net Cash
$18.3M
Return 1Y
-32.0%
Company profile
Sensus Healthcare, Inc. manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. SRT-100 is an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers.
- CEO
- Joseph C. Sardano
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 40
- Headquarters
- Florida
- Website
- sensushealthcare.com
Earnings
SRTS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.4M↓ -59.3%
Diluted EPS-$0.160.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | $27.0M | $44.5M | $24.4M | $41.8M | $27.5M |
| Gross profit | $5.2M | $17.0M | $29.6M | $14.1M | $24.4M | $11.9M |
| Operating income | -$8.2M | $4.1M | $14.8M | -$382,000.00 | $8.1M | -$10.3M |
| Net income | -$6.8M | $4.1M | $24.2M | $485,000.00 | $6.6M | -$7.7M |
| Diluted EPS | -$0.42 | $0.25 | $1.46 | $0.03 | $0.41 | -$0.47 |
| Operating cash flow | -$434,000.00 | -$286,000.00 | -$1.4M | -$2.1M | -$831,000.00 | $528,000.00 |
| Free cash flow | -$793,000.00 | -$414,000.00 | -$1.6M | -$2.4M | -$1.1M | $332,000.00 |
| Gross margin | 54.8% | 62.8% | 66.5% | 57.6% | 58.4% | 43.2% |
| Operating margin | -86.0% | 15.2% | 33.3% | -1.6% | 19.4% | -37.5% |
| Net margin | -71.4% | 15.2% | 54.4% | 2.0% | 15.9% | -28.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $8.8M | $13.1M | $8.3M | $7.3M | $6.9M | $4.9M | $3.4M |
| Gross profit | $5.4M | $5.2M | $7.1M | $4.4M | $2.9M | $2.7M | $1.9M | $991,000.00 |
| Operating income | $2.0M | $1.5M | $1.7M | -$2.6M | -$1.9M | -$2.6M | -$3.1M | -$4.4M |
| Net income | $1.6M | $1.2M | $1.5M | -$2.6M | -$1.0M | -$943,000.00 | -$3.2M | -$2.6M |
| Diluted EPS | $0.10 | $0.07 | $0.10 | -$0.16 | -$0.06 | -$0.06 | -$0.19 | -$0.16 |
| Operating cash flow | $4.2M | $4.0M | -$827,000.00 | -$2.7M | $3.1M | $2.3M | -$2.2M | -$3.8M |
| Free cash flow | $4.2M | $3.6M | -$1.1M | -$2.7M | $3.1M | $2.3M | -$2.4M | -$3.8M |
| Gross margin | 58.7% | 59.3% | 54.4% | 52.2% | 39.7% | 39.4% | 38.4% | 29.2% |
| Operating margin | 21.5% | 16.9% | 13.2% | -31.7% | -26.6% | -37.3% | -63.8% | -128.4% |
| Net margin | 17.4% | 13.7% | 11.8% | -30.8% | -14.2% | -13.7% | -64.1% | -77.4% |
Company news
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.